Scholarlink

<p>Hyperuricaemia, a metabolic disorder, is characterized by abnormally elevated serum uric acid (SUA) levels. Fructose-1,6-bisphosphatase (FBPase), a key rate-limiting enzyme in gluconeogenesis, catalyses the irreversible conversion of fructose-1,6-bisphosphate (F-1,6-BP) to fructose-6-phosphate (F-6-P). In humans, FBPase deficiency disorder (OMIM #229700) is an autosomal recessive inborn error of metabolism characterized by fasting-induced hypoglycaemia, life-threatening lactic acidosis, hyperuricaemia, and hepatosteatosis. However, the exact pathophysiological mechanisms driving hyperuricaemia remain unknown. To systematically investigate the regulatory role of FBPase in urate homeostasis, we developed in vitro models encompassing major metabolic tissues—HK-2 cells (kidney), LoVo/Caco-2 cells (intestinal epithelium) and HepG2 cells (liver). Our results demonstrate that FBP1 ablation markedly downregulates ABCG2 protein expression in renal (HK-2) and intestinal (LoVo/Caco-2) epithelial cells, thereby inducing a hyperuricaemic-prone metabolic state. Notably, in HepG2 cells, FBP1 deficiency unexpectedly led to reduced intracellular urate accumulation, indicating an inverse phenotype. Mechanistically, FBP1 sustained uric acid homeostasis through the orchestration of the PI3K/AKT/CREB signalling axis, driving functional ABCG2 expression. In summary, FBP1 plays a crucial role in uric acid metabolism, and its reduction leads to impaired uric acid excretion, consequently causing hyperuricaemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FBP1 promotes ABCG2-mediated uric acid excretion through activation of the PI3K/AKT/CREB signaling pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Qiufang Bai,
  • Chenma Wang,
  • Jun Li,
  • Yanqin Fu,
  • Yaping Xin,
  • Zhuobei Chen,
  • Zhibo Liu,
  • Dongming Zhang

摘要

Hyperuricaemia, a metabolic disorder, is characterized by abnormally elevated serum uric acid (SUA) levels. Fructose-1,6-bisphosphatase (FBPase), a key rate-limiting enzyme in gluconeogenesis, catalyses the irreversible conversion of fructose-1,6-bisphosphate (F-1,6-BP) to fructose-6-phosphate (F-6-P). In humans, FBPase deficiency disorder (OMIM #229700) is an autosomal recessive inborn error of metabolism characterized by fasting-induced hypoglycaemia, life-threatening lactic acidosis, hyperuricaemia, and hepatosteatosis. However, the exact pathophysiological mechanisms driving hyperuricaemia remain unknown. To systematically investigate the regulatory role of FBPase in urate homeostasis, we developed in vitro models encompassing major metabolic tissues—HK-2 cells (kidney), LoVo/Caco-2 cells (intestinal epithelium) and HepG2 cells (liver). Our results demonstrate that FBP1 ablation markedly downregulates ABCG2 protein expression in renal (HK-2) and intestinal (LoVo/Caco-2) epithelial cells, thereby inducing a hyperuricaemic-prone metabolic state. Notably, in HepG2 cells, FBP1 deficiency unexpectedly led to reduced intracellular urate accumulation, indicating an inverse phenotype. Mechanistically, FBP1 sustained uric acid homeostasis through the orchestration of the PI3K/AKT/CREB signalling axis, driving functional ABCG2 expression. In summary, FBP1 plays a crucial role in uric acid metabolism, and its reduction leads to impaired uric acid excretion, consequently causing hyperuricaemia.